My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Darunavir Ethanolate (DRV, Prezista)
    Darunavir Ethanolate (DRV, Prezista)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0732
    CAS #: 635728-49-3Purity ≥98%

    Description: Darunavir Ethanolate (DRV, TMC-114; UIC-94017; Trade name: Prezista), the ethanolate salt of darunavir, is a nonpeptidic HIV protease inhibitor/PI used in combination with other HIV medications to control HIV infection. Darunavir was approved by FDA in 2006 to treat and prevent HIV/AIDS infection. Darunavir is an OARAC (Office of AIDS Research Advisory Council) recommended treatment option for treatment-naive and treatment-experienced adults and adolescents. It was developed by pharmaceutical company Tibotec and was named after Arun K. Ghosh, the chemist who discovered the molecule at the University of Illinois at Chicago (now a Professor at Purdue Univeristy). Darunavir is generally recommended for use with other antiretrovirals, for example, it is often used with low doses of ritonavir or cobicistat to increase darunavir levels. It may be used for prevention after a needlestick injury or other potential exposure. It is taken by mouth once to twice a day.

    References: Biol Pharm Bull. 2009 Sep;32(9):1588-93; Expert Opin Pharmacother. 2007 Aug;8(12):1951-64.

    Related CAS: 206361-99-1 (free) 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)593.73
    CAS No.635728-49-3 (Ethanolate);
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (168.4 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    SMILES Code O=C(O[[email protected]@H]1[[email protected]@]2([H])[[email protected]@](OCC2)([H])OC1)N[[email protected]@H](CC3=CC=CC=C3)[[email protected]](O)CN(S(=O)(C4=CC=C(N)C=C4)=O)CC(C)C.CCO
    SynonymsDarunavir Ethanolate; TMC-114 Ethanolate; TMC114 Ethanolate; TMC 114 Ethanolate; UIC-94017 Ethanolate; UIC 94017 Ethanolate; UIC94017 Ethanolate; Trade name: Prezista.

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Darunavir displays potent activity against HIV strains resistant to other available protease inhibitor. Darunavir inhibits P-glycoprotein-mediated efflux of calcein-acetoxymethyl ester in L-MDR1 cells with the inhibitory potency of 121 mM. Darunavir is a protein inhibits that mimics the phenylalanine sequences at positions 167 and 168 of the gag-pol polypeptide and binds to the active sites of the HIV protease, thereby inhibiting its activity. Darunavir blocks the infectivity and replication of each of the HIV-1 variants at concentrations up to 5 μM. Darunavir shows strong ARV activity against a selected panel of 19 recombinant clinical isolates carrying multiple protease mutations conferring resistance to an average of five other protien inhibitors. Darunavir inhibits 75% of 1501 PI-resistant viruses tested with a half maximal effective concentration (EC50) of < 10 nM.

    Kinase Assay: Darunavir has a Ki of 1 nM for wild type HIV-1 protease.

    Cell Assay: In an in vitro study in MT-2 cells, the potency of darunavir is greater than that of saquinavir, amprenavir, nelfinavir, indinavir, lopinavir and ritonavir. Darunavir is primarily metabolized by the hepatic cytochrome P450 (CYP) enzymes, primarily CYP3A. The ‘boosting’ dose of ritonavir acts an an inhibitor of CYP3A, thereby increasing darunavir bioavailability

    In VivoDarunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It is often used in combination with ritonavir, which increases the bioavailability to 82%
    Animal model
    Formulation & Dosage
    ReferencesBiol Pharm Bull. 2009 Sep;32(9):1588-93; Expert Opin Pharmacother. 2007 Aug;8(12):1951-64.

    These protocols are for reference only. InvivoChem does not independently validate these methods.

     Biological activity-darunavir


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?